logo
York mum defies doctors by living years beyond expected lifespan

York mum defies doctors by living years beyond expected lifespan

BBC News15-03-2025

In 2018, Julie Blackburn was diagnosed with incurable breast cancer and given two years to live – but seven years later she is celebrating her son Henry's 13th birthday."I will never be cured, but this magnificent drug developed by Cancer Research UK is keeping me alive and for much longer than anticipated," she says."As a result, one by one I get to give Henry the letters I wrote to him, never thinking I would be here to see him read them. The last being for his 13th birthday, when he became a teenager."Ms Blackburn, 53, from Bishopthorpe on the outskirts of York, was first diagnosed with breast cancer in February 2015, after finding a lump while showering.Henry was three years old.
She had a mastectomy and reconstruction as well as three weeks of radiotherapy."Despite the shock of getting a diagnosis, everything went well and I began taking the hormone therapy drug Tamoxifen and needed check-ups every six months. I thought that was the end of it and I was grateful to have put cancer behind me," she says.But in 2018 she felt a change and discovered a new, unrelated cancer had already spread and was in her lymph nodes and bones. She was diagnosed with stage four secondary breast cancer."When you get a secondary diagnosis, they often say you have between two to five years as it becomes stage 4. But I'm living proof that it's getting better and the treatments are getting better," she says.She was prescribed Palbociclib - a chemotherapy drug that works by targeting and blocking cell cycle processes, destroying cancer cells.The drug became available to NHS patients in 2017.Now Ms Blackburn's cancer levels are the lowest they have been since her terminal diagnosis and remain stable."So while we actually have cancer, people are living with it a lot longer and things are getting a lot easier because they don't have to have such harsh treatments," she says."And even though you're still getting side effects, you can live a life."My life might be very different, but it's my life and I'm living it. I always say cancer chose to live with me and not the other way around, so I make sure it follows me on my journey."
Ms Blackburn takes the chemotherapy tablet every day for three weeks followed by a week off.She says the side effects include fatigue, being prone to infections, and a lot of sores in her mouth.But the drug also means she is around to see her son grow up – and raise money for Cancer Research UK so it can continue to develop more drugs.She says: "I never thought I'd be here. My son is now a teenager. He's 13. It's brilliant."I never thought I would see the day where I had to buy his secondary school uniform."I've got a moody teenager, but I don't care. I'm glad I've got a moody teenager because I'm alive."
Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dentists slam Welsh Government's NHS dental reforms
Dentists slam Welsh Government's NHS dental reforms

South Wales Argus

time42 minutes ago

  • South Wales Argus

Dentists slam Welsh Government's NHS dental reforms

The British Dental Association Cymru has warned the Welsh Government that the changes could lead to an exodus from the workforce and should be paused for further trials. The proposed reforms aim to improve oral health, increase prevention, and provide better value for money. However, a survey indicates that only two per cent of dentists believe the changes will support NHS dentistry's sustainability. Just five per cent agree the reforms will enhance prevention, and eight per cent think they will improve access to NHS care. A significant concern is the shift in patient appointments to up to 24 months apart, which could limit early disease detection, including oral cancers. The changes also propose moving patients to a centralised database, potentially fragmenting family care. The reforms are expected to be introduced next year.

Women with genetic cancer risk being ‘missed' due to testing gaps
Women with genetic cancer risk being ‘missed' due to testing gaps

North Wales Chronicle

timean hour ago

  • North Wales Chronicle

Women with genetic cancer risk being ‘missed' due to testing gaps

A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'

Women with genetic cancer risk being ‘missed' due to testing gaps
Women with genetic cancer risk being ‘missed' due to testing gaps

Rhyl Journal

time2 hours ago

  • Rhyl Journal

Women with genetic cancer risk being ‘missed' due to testing gaps

A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store